Jacob Hutchins1, Daniel Delaney1, Rachel Isaksson Vogel2, Rahel G Ghebre3, Levi S Downs3, Linda Carson3, Sally Mullany3, Deanna Teoh3, Melissa A Geller4. 1. Department of Anesthesiology, University of Minnesota, Minneapolis, MN, USA. 2. Masonic Cancer Center Biostatistics and Bioinformatics, University of Minnesota, Minneapolis, MN, USA. 3. Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA. 4. Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA. Electronic address: gelle005@umn.edu.
Abstract
INTRODUCTION: Optimal pain control after major surgery contributes to a patient's recovery and satisfaction. The use of liposomal bupivacaine in subcostal transversus abdominis plane (TAP) blocks for postoperative pain control after robot assisted abdominal surgery has yet to be studied. METHODS: We conducted a prospective randomized controlled observer-blinded study comparing bilateral subcostal TAP blocks with bupivacaine to bilateral subcostal TAP blocks with liposomal bupivacaine. These were performed prior to the patient undergoing robot assisted hysterectomy. The patients' pain scores, opioid use, side effects, and satisfaction were followed for 72h after injection. RESULTS:Total opioid use in the first 72h after injection was significantly decreased in the group that received liposomal bupivacaine compared to bupivacaine. Patients in the liposomal bupivacaine group had significantly lower maximal pain scores at all time periods studied as well as decreased incidence of nausea/vomiting. There was a trend toward decreased length of stay in the liposomal bupivacaine group. CONCLUSION: Subcostal TAP blocks with liposomal bupivacaine decreased the total opioid requirement for the first 72h after robot assisted hysterectomy when compared to subcostal TAP blocks with bupivacaine.
RCT Entities:
INTRODUCTION: Optimal pain control after major surgery contributes to a patient's recovery and satisfaction. The use of liposomal bupivacaine in subcostal transversus abdominis plane (TAP) blocks for postoperative pain control after robot assisted abdominal surgery has yet to be studied. METHODS: We conducted a prospective randomized controlled observer-blinded study comparing bilateral subcostal TAP blocks with bupivacaine to bilateral subcostal TAP blocks with liposomal bupivacaine. These were performed prior to the patient undergoing robot assisted hysterectomy. The patients' pain scores, opioid use, side effects, and satisfaction were followed for 72h after injection. RESULTS: Total opioid use in the first 72h after injection was significantly decreased in the group that received liposomal bupivacaine compared to bupivacaine. Patients in the liposomal bupivacaine group had significantly lower maximal pain scores at all time periods studied as well as decreased incidence of nausea/vomiting. There was a trend toward decreased length of stay in the liposomal bupivacaine group. CONCLUSION: Subcostal TAP blocks with liposomal bupivacaine decreased the total opioid requirement for the first 72h after robot assisted hysterectomy when compared to subcostal TAP blocks with bupivacaine.
Authors: Thomas G Weiser; Scott E Regenbogen; Katherine D Thompson; Alex B Haynes; Stuart R Lipsitz; William R Berry; Atul A Gawande Journal: Lancet Date: 2008-06-24 Impact factor: 79.321
Authors: Marie Fidela R Paraiso; Beri Ridgeway; Amy J Park; J Eric Jelovsek; Matthew D Barber; Tommaso Falcone; Jon I Einarsson Journal: Am J Obstet Gynecol Date: 2013-02-08 Impact factor: 8.661
Authors: Selvan Pather; John Anthony Loadsman; Pragasan Dean Gopalan; Archana Rao; Shannon Philp; Jonathon Carter Journal: Aust N Z J Obstet Gynaecol Date: 2011-09-16 Impact factor: 2.100
Authors: John F Boggess; Paola A Gehrig; Leigh Cantrell; Aaron Shafer; Mildred Ridgway; Elizabeth N Skinner; Wesley C Fowler Journal: Am J Obstet Gynecol Date: 2008-10 Impact factor: 8.661
Authors: Gary M Oderda; Qayyim Said; R Scott Evans; Gregory J Stoddard; Jim Lloyd; Kenneth Jackson; Dale Rublee; Matthew H Samore Journal: Ann Pharmacother Date: 2007-03-06 Impact factor: 3.154
Authors: Dennis E Feierman; Mark Kronenfeld; Piyush M Gupta; Natalie Younger; Eduard Logvinskiy Journal: J Pain Res Date: 2014-08-16 Impact factor: 3.133
Authors: Taylor J Aiken; Elena Padilla; Deborah Lemaster; Sean Ronnekleiv-Kelly; Sharon Weber; Rebecca M Minter; Steven Ethier; Daniel E Abbott Journal: J Surg Oncol Date: 2021-10-07 Impact factor: 3.454
Authors: Thomas W Hamilton; Vassilis Athanassoglou; Marialena Trivella; Louise H Strickland; Stephen Mellon; David Murray; Hemant G Pandit Journal: Cochrane Database Syst Rev Date: 2016-08-25